Related references
Note: Only part of the references are listed.Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
David A. Lipson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
Shiyuan Zhang et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020)
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study A Randomized, Double-Blind, Multicenter Clinical Trial
MeiLan K. Han et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis
Benjamin F. Hartley et al.
RESPIRATORY RESEARCH (2020)
Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease A Systematic Review and Meta-analysis
Manoj J. Mammen et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals
S. Gaduzo et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Status of and strategies for improving adherence to COPD treatment
Jose Luis Lopez-Campos et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
Steven Pascoe et al.
LANCET RESPIRATORY MEDICINE (2019)
A phase III study of triple therapy with budesonide/glycopyrrolate/ formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
Klaus F. Rabe et al.
RESPIRATORY MEDICINE (2019)
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
Francois Maltais et al.
RESPIRATORY RESEARCH (2019)
Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019
David M. G. Halpin et al.
ECLINICALMEDICINE (2019)
Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease
Kieran J. Rothnie et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
Alberto Papi et al.
LANCET (2018)
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised
Steve Pascoe et al.
LANCET RESPIRATORY MEDICINE (2018)
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
Mona Bafadhel et al.
LANCET RESPIRATORY MEDICINE (2018)
Inhaled corticosteroids in COPD: friend or foe?
Alvar Agusti et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Inhaled corticosteroid containing combinations and mortality in COPD
Jorgen Vestbo et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Current appraisal of single inhaler triple therapy in COPD
Brian Lipworth et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Gary T. Ferguson et al.
LANCET RESPIRATORY MEDICINE (2018)
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
Lowie Vanfleteren et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis
John R. Hurst et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD
Nicholas P. Williams et al.
RESPIRATORY RESEARCH (2018)
Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
Marcos I. Restrepo et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2018)
Assessing Short-term Deterioration in Maintenance naive Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
M. Reza Maleki-Yazdi et al.
ADVANCES IN THERAPY (2017)
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
Jorgen Vestbo et al.
LANCET (2017)
Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A. Papi et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
Impact and prevention of severe exacerbations of COPD: a review of the evidence
David M. G. Halpin et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice
James D. Chalmers et al.
NPJ PRIMARY CARE RESPIRATORY MEDICINE (2017)
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease
David A. Lipson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis
Yuji Oba et al.
THORAX (2016)
A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD
Luigino Calzetta et al.
CHEST (2016)
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study
Claus Vogelmeier et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
Dave Singh et al.
LANCET (2016)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Jadwiga A. Wedzicha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective
MeiLan K. Han et al.
LANCET RESPIRATORY MEDICINE (2016)
Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational
Kevin Gruffydd-Jones et al.
NPJ PRIMARY CARE RESPIRATORY MEDICINE (2016)
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers
Andrew P. Yu et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Effects of tiotropium plus olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
Dave Singh et al.
RESPIRATORY RESEARCH (2016)
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease-The Shifting Treatment Paradigm
Morven Wilkie et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life
Dave Singh et al.
RESPIRATORY MEDICINE (2015)
The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK
Guy Brusselle et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit
Aarash Saleh et al.
PLOS ONE (2015)
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
Eric D. Bateman et al.
RESPIRATORY RESEARCH (2015)
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study
Donald A. Mahler et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations
J. A. Wedzicha et al.
RESPIRATORY MEDICINE (2014)
Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns
David Price et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
Marc Decramer et al.
LANCET RESPIRATORY MEDICINE (2014)
Quantifying Health Services Use for Chronic Obstructive Pulmonary Disease
Andrea S. Gershon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD
Mika J. Makela et al.
RESPIRATORY MEDICINE (2013)
Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: A population-based Danish cohort study
Sigrun A. Johannesdottir et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
The clinical and economic burden of chronic obstructive pulmonary disease in the USA
Anthony J. Guarascio et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Acute Exacerbations of COPD in the United States: Inpatient Burden and Predictors of Costs and Mortality
Prasadini N. Perera et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2012)
Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study
Amir Sharafkhaneh et al.
RESPIRATORY MEDICINE (2012)
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes
Thys van der Molen et al.
PRIMARY CARE RESPIRATORY JOURNAL (2012)
Exacerbation frequency and course of COPD
David M. G. Halpin et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2012)
COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population
Monica J. Fletcher et al.
BMC PUBLIC HEALTH (2011)
Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis
Kathryn Fitch et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
Mario Cazzola et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Outcomes of Severe COPD Exacerbations Requiring Hospitalization
Praveen R. Chenna et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Severe exacerbations and BODE index: Two independent risk factors for death in mate COPD patients
Juan Jose Soler-Cataluna et al.
RESPIRATORY MEDICINE (2009)
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide
Jadwiga A. Wedzicha et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
Peter M. A. Calverley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
JJ Soler-Cataluña et al.
THORAX (2005)
The effects of a smoking cessation intervention on 14.5-year mortality - A randomized clinical trial
NR Anthonisen et al.
ANNALS OF INTERNAL MEDICINE (2005)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD
M Miravitlles et al.
CHEST (2002)
The costs of treating COPD in the United States
SA Strassels et al.
CHEST (2001)
Share Paper
